{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-071988","form_type":"8-K","ticker":"PVLA","cik":"0001583648","company_name":"PALVELLA THERAPEUTICS, INC.","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.879543+00:00","generated_at":"2026-05-21T04:59:37.360047+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Palvella Phase 3 SELVA enrollment surpasses target; cash $75.6M extends runway into H2 2027","bullets":["Phase 3 SELVA for microcystic LM exceeded 40-patient enrollment; closes June 2025, top-line Q1 2026.","Phase 2 TOIVA for cutaneous VM enrolled first patients; top-line results on track for Q4 2025.","Cash and equivalents $75.6M at March 31, 2025; funds operations into second half of 2027.","Net loss $8.2M ($0.74 per share) vs $2.7M loss in prior-year period; R&D $4.1M, G&A $3.8M.","Patent granted for QTORIN rapamycin in microcystic LM; IP extends into 2038."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-071988","json":"https://secwatch.observer/filing/0000950170-25-071988.json","markdown":"https://secwatch.observer/filing/0000950170-25-071988.md","text":"https://secwatch.observer/filing/0000950170-25-071988.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583648/000095017025071988/0000950170-25-071988-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583648/000095017025071988/pvla-20250515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T04:59:37.360047+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}